<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02484482</url>
  </required_header>
  <id_info>
    <org_study_id>148FDI15009</org_study_id>
    <nct_id>NCT02484482</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519(CKD-519 FDI)</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, 3-treatment, 3-period, 6-sequence Crossover Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519 After Oral Administration in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <brief_summary>
    <textblock>
      The purpose this study investigate the effect of food on the
      pharmacokinetics/pharmacodynamics and safety of CKD-519
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of CKD-519</measure>
    <time_frame>0(predose), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma drug concentration-time curve(AUC0-last) of CKD-519</measure>
    <time_frame>0(predose), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ of CKD-519</measure>
    <time_frame>0(predose), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of CKD-519</measure>
    <time_frame>0(predose), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of CKD-519</measure>
    <time_frame>0(predose), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F(Clearance/Bioavailability) of CKD-519</measure>
    <time_frame>0(predose), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vd/F of CKD-519</measure>
    <time_frame>0(predose), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inhibition of CETP(Cholesteryl ester transfer protein) Activity</measure>
    <time_frame>0(predose), 1, 2, 4, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
Fasting→Standard Meal→High Fat Meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
Standard Meal→High Fat Meal→Fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
High Fat Meal→Fasting→Standard Meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
Fasting→High Fat Meal→Standard Meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
Standard Meal→Fasting→High Fat Meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
High Fat Meal→Standard Meal→Fasting</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519 200mg / Fasting, Standard Meal, High Fat Meal</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between 19 aged and 55 aged in healthy adult

          2. Body weight more than 55kg in male, 50kg in female

          3. Body Mass Index more than 18.5 and under 25(body mass index=kg/m2)

          4. If female, must include more than one among the items

               -  The menopause(there is no natural menses for at least 2 years)

               -  Surgical Infertility(hysterectomy or bilateral oophorectomy, tubal ligation or
                  other methods of infertility condition)

          5. If men has sexual life with women of childbearing age, Necessarily he agrees that use
             condoms and do not sperm donation until two months during clinical trials and after
             the final dosage of investigational products

          6. Those who fully understand about this clinical trials after enough hearing, and then
             decided to join the clinical trials by themselves and to comply with the precautions
             written consent

        Exclusion Criteria:

          1. Have clinically significant disease that hepatobiliary system(severe hepatic
             impairment, etc.), kidney(severe renal impairment, etc.), nervous system, immune
             system, respiratory system, endocrine system, haemato-oncology disease, cardiovascular
             system(heart failure, etc.) or mental illness, or a history of mental disease.

          2. Have a gastrointestinal disease history that can effect drug absorption(Crohn's
             disease, ulcers, etc.) or surgery(except simple appendectomy or hernia surgery)

          3. Hypersensitivity reaction or clinically significant hypersensitivity reaction in the
             history of drugs or additives.

          4. An impossible one who participates in clinical trial including screening tests
             (medical history taking, BP, 12-lead ECG, physical examination, blood&amp;urine laboratory
             test result) before 28 days the taking investigational products.

          5. Defined by the following laboratory parameters

               -  AST(Aspartate aminotransferase), ALT(Alanine aminotransferase)&gt;1.25* upper limit
                  of normal range

               -  Total bilirubin&gt;1.5* upper limit of normal range

               -  CPK(Creatine phosphokinase)&gt;1.5* upper limit of normal range

               -  eGFR(Estimated Glomerular Filtration Rate, using by MDRD(Modification of Diet in
                  Renal Disease) method)&lt;60 mL/min/1.73m2

          6. Sitting SBP(Systolic Blood Pressure )&gt;150 mmHg or &lt;90 mmHg, sitting DBP(Diastolic
             Blood Pressure )&gt;100 mmHg or 50 mmHg , after 5 minutes break.

          7. Drug abuse or have a history of drug abuse shows a positive for urine drug test.

          8. Pregnant or lactating women.

          9. A heavy caffeine consumer(caffeine&gt;5 cups/day), alcohol consumer(alcohol&gt;210g/week),
             or smoker(cigarette&gt;10 cigarettes/day)

         10. Subject takes ethical drug or herbal medicine within 14 days, OTC(Over The Counter
             Drug) within 7 days before the beginning of study treatment but investigator determine
             that the taking drug affect this study or could affect the safety of subjects

         11. Subject who takes inhibitor and inducers of drug metabolizing enzyme(Barbiturates
             etc.) within 30days.

         12. Taking foods containing grapefruit within 7 days before the beginning of study
             treatment(ex. Drinking containing grapefruit of 1 liter per a day or more within 7days
             before the beginning of study treatment)

         13. Subject who treated with any investigational drugs within 90 days before the beginning
             of study treatment.

         14. Previously donate whole blood within 60 days or component blood within 30days.

         15. An impossible one who participants in clinical trial by investigator's decision
             including laboratory test result or another reason.

         16. Positive for Serology test(Hepatitis B, Hepatitis C, HIV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-gu</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2015</study_first_submitted>
  <study_first_submitted_qc>June 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2015</study_first_posted>
  <last_update_submitted>December 4, 2015</last_update_submitted>
  <last_update_submitted_qc>December 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

